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=Abstract=Recently, there has been a proliferation of experimental and clinical data
supporting early androgen deprivation for advanced prostatic cancer, due to the new
insights provided by a more thorough understanding of prostate cancer biology. The
logn term survival of patients with prostatic metastatic disease will require the develop-
ment of novel treatment strategies truly effective against anti-androgen-resistant tumor
cells and their use in concert with early androgen deprivation. To date, no evidence has
been generated in experimental animal or human models of prostate cancer that
supports the previous concept of delayed hormonal therapy.
The development of luteinizing hormone-releasing hormone (LHRH) agonists and
the anti-androgens has prompted a resurgence of interest in initial total androgen
blockade, and the inhibition of the activity of 5-alpha reductase could provide a safe
and effective way to remove prostatic intraepithelial dihydrotestosterone, resulting in a
diminishing production of growth factors. The rationale for the use of Sumarin in the
treatment of stage D prostatic cancer refractory to conventional hormonal manipu-
lation is its ability to block the activity of several growth factors, including basic fibro-
blast growth factor (bFGF) and epidermal growth factor (EGF), etc. which have been
postulated to have important roles in prostatic cell biolgy.
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Since the landmark observations ot
Huggins and Hodges in 1941, androgen depri-
vation has been the mainstay of treatment for
advanced-stage prostate cancer. Although
early, poorly controlled studies suggested
enhanced survival with hormonal therapy. this
view fell into disfavor as a result of the
observations of the first and second Veterans
Administration Cooperative Urological Res-
earch Group (VACURG) studies. Recently.
there has been a proliferation of experimental
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and clinical data supporting early androgen
deprivation. including a reanalysis of the
VACURG data, which suggests a survival ad-
vantage for younger patients with stage 0 dis-
ease and high-grade tumors who undergo
addrogen-ablative therapy at the time of diag-
nosis. The riskbenefit analysis presented in this
review is strongly supportive of early hormonal
therapy. Finally. long-term survival of patients
with metastatic prostate cancer will req uire the
development of novel treatment strategies effec-
tive against anti-androgen-resistant tumor cells
and their use in concert with early androgen
deprivation.















